A

Amgen

Makes biotech medicines for serious illnesses

Senior Associate Data Scientist

Full-Time
No salary listed
Junior
Bachelor's, Master's
Hyderabad, Telangana, India
In Person
AI & Machine LearningApplied Machine Learning

About the job

Requirements
  • Experience with one or more analytical software tools or languages such as R and Python.
  • Foundational understanding of the U.S. pharmaceutical ecosystem, relevant datasets such as claims and prescriptions, and patient support services such as copay programs.
  • Strong foundation in machine learning algorithms and techniques.
  • Experience with statistical techniques and hypothesis testing, including regression analysis, clustering, and classification.
  • A Master's degree in computer science, statistics, or STEM majors and at least 2 years of Information Systems experience, or a Bachelor's degree in computer science, statistics, or STEM majors and at least 4 years of Information Systems experience.
Responsibilities
  • Work with the broader U.S. Value & Access Transformation team to develop and test AI and advanced statistical solutions addressing priority business challenges.
  • Ensure models are trained with the latest data and meet service-level agreement expectations.
  • Act as a subject matter expert in solving development and commercial questions.
  • Work with a global cross-functional team on the AI tool roadmap.
  • Work in technical teams on the development, deployment, and application of applied, predictive, and prescriptive analytics.
  • Use hypothesis testing, machine learning, retrieval processes, statistical methods, and data-mining techniques to identify trends, create figures, and analyze relevant information.
  • Perform exploratory and targeted data analyses using descriptive statistics and other methods.
  • Develop model and analytics experiment pipelines leveraging MLOps.
  • Collaborate with technical teams to translate business needs into technical specifications, focusing on AI-driven automation and insights.
  • Develop and integrate custom applications, intelligent dashboards, and automated workflows that incorporate AI capabilities to enhance decision-making and efficiency.
Desired Qualifications
  • Experience with MLOps practices and tools such as MLflow, Kubeflow, and Airflow, and DevOps tools such as Docker, Kubernetes, and continuous integration/continuous delivery.
  • Proficiency in Python and relevant machine-learning libraries such as TensorFlow, PyTorch, and scikit-learn.
  • Experience with data engineering and pipeline development.
  • Knowledge of natural language processing techniques for text analysis and sentiment analysis.
  • Experience analyzing time-series data for forecasting and trend analysis.
  • Experience with AWS, Azure, or Google Cloud.
  • Experience with the Databricks platform for data analytics and MLOps.
  • Any AWS Developer certification is preferred.
  • Any Python and machine-learning certification is preferred.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, CA

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

Yahoo Finance
Nov 2nd, 2026
Amgen Q3 preview: revenue seen up 5.2% after $10.05B last quarter, shares up 15.6% in a month

Amgen (NASDAQ:AMGN) reports third-quarter results on Tuesday after market close. Analysts expect revenue to grow 5.2% year on year, down from 12.4% in the same quarter last year. Last quarter, the biotech company beat revenue expectations with $10.05 billion, up 9.5%. It also raised full-year revenue guidance above analyst estimates. Peers have reported already. Biogen's revenue rose 10.6%, and its shares fell 1.2%; Gilead Sciences' revenue rose 6.8%, and its shares gained 4.1%. Amgen shares are up 15.6% over the past month, trading at $466.00. The average analyst price target is $397.32.

Yahoo Finance
Oct 31st, 2026
Amgen offers growth, income and stability, with revenue up 10% to $10.1B and a 2.3% yield

Amgen, the biotech giant, offers a mix of growth, income, and stability, according to a Motley Fool analysis. Second-quarter revenue rose 10% year over year to $10.1 billion, despite the coming loss of patent exclusivity for bone drug denosumab. Newer drugs such as Tezspire, Tepezza, and Imdelltra are driving sales. Imdelltra, combined with Imfinzi, cut the risk of death by 58% in a Phase 3 trial in certain small-cell lung cancer patients. Amgen's shares rose about 16% in 2022 as broader equities fell. It has raised its dividend every year since 2011, and the payout has grown 152% over the past decade. The forward yield is 2.3%, against 1.1% for the S&P 500.

Ars Technica
Oct 31st, 2026
FDA seeks to pull Tavneos over alleged data manipulation, but Amgen fights back

The US Food and Drug Administration (FDA) wants to withdraw approval of Tavneos, a drug for a rare autoimmune vasculitis, saying it was approved on manipulated trial data. In April, it sent Amgen a letter citing serious, sometimes fatal, liver injury and a lack of "substantial evidence" that the drug works. The FDA alleges ChemoCentryx, which Amgen bought for nearly $4 billion a year after approval, reassessed selected patients after unblinding the data and did not disclose it. Amgen says no clinical data were altered and the drug should stay available. Tavneos sales reached nearly half a billion dollars in fiscal year 2025. The EU has pulled the drug, the UK plans to, and a journal retracted the trial paper. A court hearing on a proposed $69 million investor settlement is expected on October 29.

PR Newswire
Oct 26th, 2026
Amgen appoints former Yum! Brands CEO David Gibbs to its board

Amgen has appointed David W. Gibbs to its board of directors, effective immediately. He will serve on the Audit Committee and the Compensation and Management Development Committee. Gibbs recently retired as president and chief executive officer of Yum! Brands, owner of Taco Bell and Kentucky Fried Chicken. As chief executive from 2020 to 2025, he led its digital transformation and expanded it to nearly 61,000 locations. He has sat on the board of Under Armour since 2021 and PepsiCo since 2026. "His experience creating direct relationships with customers will help inform how we prepare for future launches," said Robert A. Bradway, Amgen's chairman and chief executive officer. The board now has 13 directors, 12 of them independent.

Yahoo Finance
Oct 26th, 2026
ESMO 2026: Moderna vaccine debate, Roche's $3.6B KRAS bet and Amgen's lung cancer data

Three cancer drug trials drew attention at the European Society for Medical Oncology (ESMO) meeting, with investors and analysts weighing the results. Moderna and Merck's vaccine intismeran autogene cut the relative risk of melanoma recurrence or death by 42% in a Phase 3 trial. Moderna's shares have still fallen by double digits since the results leaked early, as investors question its valuation and the vaccine's manufacturing and commercial potential. Roche's divarasib reduced the risk of death or disease progression by 42% in KRAS G12C lung cancer, beating Krazati and Lumakras. Patients lived a median of about 18 months, versus a year. Roche raised its peak sales forecast from 3.6 billion Swiss francs to 3 billion. Amgen's Imdelltra, combined with Imfinzi, cut the risk of death by 58% in small cell lung cancer. Median survival was 21.1 months, against 12.7 months for Imfinzi alone.